Gensight Biologics SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Laurence Rodriguez
- Full Time Employees
- 13
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 74, rue du Faubourg Saint-Antoine Paris IF France 75012
- IPO Date
- Jul 13, 2016
- Website
- gensight-biologics.com
- Similar Companies
- Business
- GenSight Biologics S.A. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Founded in 2012 and headquartered in Paris, France, GenSight Biologics leverages two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its product pipeline includes GS010 (LUMEVOQ), a recombinant AAV2-based gene therapy for Leber Hereditary Optic Neuropathy (LHON) currently in Phase III clinical trials; GS030, a gene therapy in Phase I/II trials targeting Retinitis Pigmentosa; and GS040, in preclinical development for dry age-related macular degeneration. These candidates are designed as single intravitreal injections aiming for sustainable functional visual recovery in patients suffering from severe retinal diseases. Recent major developments include a successful fundraising round in November 2025 amounting to approximately EUR 2 million from existing shareholders, supporting ongoing clinical and regulatory activities. GenSight has established a strategic manufacturing partnership with Catalent, which achieved successful tech transfer and drug product batch manufacturing in November 2024, bolstering the supply chain for its clinical trials and regulatory submissions. The company is actively engaging regulatory authorities in the US, EU, and UK to align on LUMEVOQ's approval pathway, with plans to restart the Compassionate Access Program (AAC) in France by Q4 2025. Additional clinical follow-ups for the Phase III REFLECT study are ongoing with topline results expected soon, reinforcing the therapeutic potential of its lead candidates. Operating primarily in the ophthalmology and gene therapy biotechnology sectors, GenSight Biologics targets patients suffering from rare mitochondrial and degenerative retinal disorders globally. It continues to focus on innovation in gene therapy to address urgent unmet needs in vision loss diseases, establishing itself as a forefront clinical-stage biopharma entity dedicated to treating blinding retinal conditions and central nervous system impairments through advanced biotechnology solutions designed for long-lasting patient impact.
Company News
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders
GenSight Biologics Reports Cash Position as of September 30, 2026
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
GenSight Biologics Provides September 2026 Business Updates
Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
GenSight Biologics to Hold its Combined General Meeting on May 19, 2026
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
GenSight Biologics Announces the Filing of its 2025 Universal Registration Document
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026